A Earnings Prediction
The chart below shows how A performed 10 days before and after its earnings report, based on data from the past quarters. Typically, A sees a -1.25% change in stock price 10 days leading up to the earnings, and a +1.71% change 10 days following the report. On the earnings day itself, the stock moves by -0.34%. This data can give you a slight idea of what to expect for the next quarter's release.
A Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.70B
0.77%
7.79%
Gross Margin
53.91%
-0.55%
-1.87%
Operating Margin
24.28%
0.46%
-4.22%
Net Margin
20.63%
-26.69%
15.44%
EPS
1.23
-23.13%
26.80%
No Data Available
A Earnings Analysis
Agilent Technologies Inc. Corporation (A.N) Earnings Conference Call
Positive
Quarterly Revenue Improvement: Agilent reported fourth quarter revenue of $1.701 billion, reflecting a sequential improvement of over 400 basis points from Q3.
Market Recovery Indicators: The company achieved a book-to-bill ratio greater than one, indicating steady market recovery and strong demand.
Cash Flow and Shareholder Returns: Agilent's operating cash flow was $481 million in the quarter, contributing to over $400 million returned to shareholders through share repurchases and dividends.
Life Sciences Revenue Decline: The Life Sciences and Applied Markets Group reported $833 million in revenue, showcasing a 1% decline but strong performance in diagnostics and genomics.
EPS Exceeds Expectations: Agilent's EPS for Q4 was $1.46, exceeding expectations and representing a 6% increase from the previous year.
Negative
Q4 Revenue Decline: Q4 revenue was $1.701 billion, a decline of 0.3% core but a sequential improvement of over four hundred basis points from Q3.
Revenue Decline in Life Sciences: The Life Sciences and Applied Markets Group reported $833 million in revenue, representing a 1% decline as instrument volumes continued to be constrained by conservative customer CapEx spending.
Diagnostics Revenue Decline: In the Diagnostics and Genomics Group, revenue posted $442 million, representing a 3% decline that was slightly above expectations.
Global Pharma Revenue Decline: Pharma saw solid growth globally, but was offset by expected softness in NEDS and cell analysis instruments, with a 1% decline in revenue.
Market Segment Decline: Food was down 3% versus last year, while our academia and government market was down 1%.
A FAQs
How does A typically perform around its earnings report dates?
Is Agilent Technologies, Inc. (A) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
A Earning Call Sentiment
Agilent Technologies, Inc. (A) Q4 2024 Earnings Call Transcript
1.0x
00:00
00:00
A.N
-0.32%Positive
The earnings call reveals positive financial performance with EPS growth and strong cash flow, despite a slight decline in gross margin. The Q&A highlights optimism in China and growth areas like genomics and PFAS. Concerns about tariffs are mitigated by supply chain diversification. Shareholder returns are robust, and guidance suggests a recovery. The sentiment is slightly tempered by unclear responses on tariffs, but overall, the outlook is positive, likely leading to a stock price increase in the next two weeks.